MarketInOut Stock Screener Log In | Sign Up

Omeros Corp

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Omeros Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,334.84 mln
Float69.28 mln
Earnings Date11/11/2026

EPS

1.22
Moderate

P / E

15.11
Moderately valued

Piotroski F-Score

6 / 9
Solid

1-Year Forecast

27.50
Exceptional upside

Relative Strength

94 / 100
Top performer

Pre-Tax Margin

309%
Exceptional margin

Business Description

Omeros Corporation is a Seattle-based drug development company founded in 1994 that focuses on treatments for rare immune system diseases. Its most advanced drug candidate, Narsoplimab, targets a serious complication of stem cell transplants and has also been studied as a potential treatment for COVID-19. The company has several other medicines in various stages of testing, addressing conditions ranging from addiction and movement disorders to blood cancers and drug-resistant infections.

Key Fundamentals

EPS1.22
P/E15.11
ROE-109
RPS0.55
ROIC-41.65
ROA48.57
Interest Cover-3.28
EBITDA, mln128
EV / EBITDA12.44
EV / EBIT12.53
Revenue, mln38.42
EV / Revenue41.58

Quote Details

Last 18.44
Change -0.51 (-2.69%)
Open 18.53
Volume 884,308
Turnover 16,306,641
Average Volume 1,152,941

Financial Ratios

Pre-Tax Profit Margin309
Current Ratio1.95
Price / Sales38.36
PEG Ratio0.21

Financial Strength

Altman Z-Score-0.05
Piotroski F-Score 6 / 9
1-Year Target Price27.50
Short Ratio8.63
Short % of Float16.37

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 11.29% 95 / 100   
1 Month -0.16% 59 / 100   
2 Months 62.61% 98 / 100   
6 Months 22.44% 90 / 100   
1 Year 140% 98 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog